A detailed history of Wells Fargo & Company transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 55,245 shares of SUPN stock, worth $2.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,245
Previous 48,801 13.2%
Holding current value
$2.01 Million
Previous $1.66 Million 11.24%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.99 - $33.85 $167,479 - $218,129
6,444 Added 13.2%
55,245 $1.48 Million
Q1 2024

May 10, 2024

BUY
$27.11 - $35.17 $63,084 - $81,840
2,327 Added 5.01%
48,801 $1.66 Million
Q4 2023

Feb 09, 2024

SELL
$22.72 - $29.68 $12,473 - $16,294
-549 Reduced 1.17%
46,474 $1.34 Million
Q3 2023

Nov 13, 2023

SELL
$27.57 - $32.91 $407,236 - $486,113
-14,771 Reduced 23.9%
47,023 $1.3 Million
Q2 2023

Aug 15, 2023

BUY
$29.91 - $38.73 $301,223 - $390,049
10,071 Added 19.47%
61,794 $1.86 Million
Q1 2023

May 12, 2023

BUY
$34.93 - $42.03 $352,443 - $424,082
10,090 Added 24.24%
51,723 $1.87 Million
Q4 2022

Feb 13, 2023

SELL
$31.09 - $37.88 $243,279 - $296,411
-7,825 Reduced 15.82%
41,633 $1.49 Million
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $109,574 - $134,770
-3,806 Reduced 7.15%
49,458 $1.67 Million
Q2 2022

Aug 12, 2022

SELL
$25.33 - $34.25 $1.35 Million - $1.82 Million
-53,174 Reduced 49.96%
53,264 $1.54 Million
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $351,471 - $405,591
-12,328 Reduced 10.38%
106,438 $3.44 Million
Q4 2021

Feb 14, 2022

SELL
$26.37 - $34.22 $623,413 - $808,995
-23,641 Reduced 16.6%
118,766 $3.46 Million
Q3 2021

Nov 15, 2021

BUY
$23.54 - $31.39 $407,147 - $542,921
17,296 Added 13.82%
142,407 $3.8 Million
Q2 2021

Aug 16, 2021

SELL
$26.72 - $33.19 $2.33 Million - $2.89 Million
-87,065 Reduced 41.03%
125,111 $3.85 Million
Q1 2021

May 13, 2021

BUY
$24.15 - $31.45 $1.9 Million - $2.48 Million
78,857 Added 59.15%
212,176 $5.56 Million
Q4 2020

Feb 09, 2021

SELL
$17.7 - $25.81 $128,289 - $187,070
-7,248 Reduced 5.16%
133,319 $3.35 Million
Q3 2020

Nov 05, 2020

BUY
$20.2 - $25.05 $240,703 - $298,495
11,916 Added 9.26%
140,567 $2.93 Million
Q2 2020

Aug 13, 2020

BUY
$17.09 - $24.89 $164,439 - $239,491
9,622 Added 8.08%
128,651 $3.06 Million
Q1 2020

May 14, 2020

BUY
$14.45 - $24.69 $1.72 Million - $2.94 Million
119,029 New
119,029 $2.14 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.95B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.